OEM News

FDA OKs Bruno Vision Care’s Deseyne Contact Lens with Controlled-Release Tech

The company plans to make Deseyne lenses available to consumers in Q4 2025.

Author Image

By: Sam Brusco

Associate Editor

Bruno Vision Care has earned U.S. Food and Drug Administration (FDA) approval for its Deseyne (vifilcon C) daily disposable contact lens with its FusionTechnology.

Deseyne lenses integrate two patented innovations. One it’s the lens material vifilcon C, an enriched hydrogel material. The other is the FusionTechnology delivery system.

During manufacturing, bioactive substances called Lachryceuticals, which include amino acids, vitamins, and polysaccharides, are embedded in the lens matrix. Because of a patented controlled release mechanism, these substances are gradually delivered from the contact lens to the eye’s anterior segment. This guarantees bioavailability during the wearing period.

FusionTechnology combines hyaluronic acid (HA) with Tamarind Seed Polysaccharides (TSP) to create a natural bio-copolymer that resembles tears. Thie substance is steadily released, activated by body temperature, blinking, and eyelid pressure.

The company plans to make Deseyne lenses available to consumers in Q4 2025.

“Deseyne isn’t just another contact lens, it defines a completely new category by incorporating a patented delivery system directly into the lens,” said Eddie Catalfamo, CEO of Bruno Vision Care. “With our patented FusionTechnology proprietary manufacturing process and the novel vifilcon C material, we’re setting a new standard in vision health. The result is a lens that allows more people to wear contacts comfortably, provides existing wearers with greater hydration and clearer vision, and makes fitting easier for eye care professionals. It’s a true breakthrough for the industry and a game-changer for consumers.”

“There is nothing like the Deseyne lens with FusionTechnology on the market today,” said Paul Karpecki, O.D., a leader in the field of dry eye disease for over twenty-five years. “The unique design releases Lachryceuticals—key components of the tear film—in a controlled, continuous manner throughout the day, maintaining eye hydration and comfort that no other lens can achieve. Dryness is the leading cause of performance issues in contact lens wearers and the primary reason over 18% of these patients drop out each year. This lens promotes ocular health and provides a level of comfort unmatched by anything else in the industry.”

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters